---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-033242"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2024-07-16T23:59:59+00:00"
generated_at: "2026-05-31T20:24:38.951041+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q4 pro forma revenue $71.1M; FY2025 outlook $282-288M, share buyback $15M

## Summary
- Pro forma Q4 net sales $71.1M (+1.9% YoY); Med Tech +11.3% to $29.3M, Med Device -3.8% to $41.8M.
- GAAP net loss per share $0.33; adjusted loss per share $0.05, improving from $0.11 loss a year ago.
- FY2025 guidance: net sales $282-288M, Med Tech growth 10-12%, Med Device growth 1-3%, adjusted EPS loss $0.38-0.42.
- Board authorized $15M share repurchase program; no long-term debt, $76.1M cash at May 31, 2024.
- Received FDA clearance and CE Mark for AlphaVac F18 in pulmonary embolism; settled decade-long IP litigation with BD/Bard.

## SEC filing metadata
- accession: 0001140361-24-033242
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2024-07-16T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000114036124033242/0001140361-24-033242-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000114036124033242/ef20032488_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-033242
- JSON: https://secwatch.observer/filing/0001140361-24-033242.json
- Plain text: https://secwatch.observer/filing/0001140361-24-033242.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.